<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>10363424</identifier>
<setSpec>0300-9041</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Gutiérrez Nájar, A</dc:author>
<dc:author>Cedillo, F J</dc:author>
<dc:author>Verez Ruíz, J R</dc:author>
<dc:author>Contreras Bretherton, C</dc:author>
<dc:author>Das Neves, D</dc:author>
<dc:author>David Vargas, R</dc:author>
<dc:author>Bernal, M A</dc:author>
<dc:author>Stern Colin y Nunes, J J</dc:author>
<dc:author>Vilchez, R</dc:author>
<dc:description xml:lang="en">There were no differences in both groups as tho the age of the patients; received doses of both types of FSH, nor HMG; but there was as to the amount of captured ovocytes, amount, and quality, embrionary, in special 1+ 2+ in favor of the group that received urofolitropine, specially under 35 years of age. In this study there was better qualy and amount, embrionary, obtained with the use of urofolitropine, as compared with FSH recombinant for in vitro fertilization.</dc:description>
<dc:type>Clinical Trial</dc:type>
<dc:language>es</dc:language>
<dc:date>1999 May </dc:date>
<dc:title xml:lang="es">Calidad embrionaria en la utilización de urofolitropina vs FSH recombinante para fertilización in vitro.</dc:title>
<dc:title xml:lang="en">[Embryonic quality in the use of urofolitropin vs recombinant FSH for in vitro fertilization].</dc:title>
<dc:publisher>Ginecologia y obstetricia de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
